Here are the results of Deutsche Bank AG’s thorough investigation into Fresenius SE stock.

Deutsche Bank Research has left Fresenius at “Buy” with a price target of 55 euros. The concerns in the German Federal Council about state cuts in hospitals could benefit them, wrote Falko Friedrichs in a study available on Tuesday. The Statutory Health Insurance Contribution Stabilization Act met with widespread resistance in the state chamber.

Stock analysis online: The Fresenius SE share under the microscope of current analyzes and valuations

The Fresenius SE share ran out of steam in XETRA trading. At 9:48 a.m. the paper lost 0.2 percent to EUR 38.78. So the share still has an upside potential of 41.83 percent, measured against the specified price target. Most recently, the XETRA volume rose to 57,764 Fresenius SE shares. Since the beginning of 2026, the share price has fallen by 18.6 percent.

FRANKFURT (dpa-AFX Analyzer) / editorial team finanzen.net

Publication of the original study: Date not specified in study / Time not specified in study / CET
First distribution of the original study: June 16, 2026 / 07:55 / CET

Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 Para. 1 WpHG, Art. 20 Regulation (EU) 596/2014 for the analyst firm mentioned can be found at http://web.dpa-afx.de/offenlegenspflicht/offenlegens_pflicht.html.

Selected leverage products on Fresenius

With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Fresenius

Risk warning: Suffer on average 7 out of 10 retail investors Losses when trading with turbo certificates. Turbo certificates are high-risk products and not suitable for long-term investment strategies.

Advertising

ttn-28